Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Lundquist Institute For Biomedical Innovation AT Harbor-Ucla Medical Center currently manages 3 pending office actions. These matters are situated in the Biotechnology & Pharmaceuticals technology area and are assigned to 3 distinct examiners. Furthermore, the 3 pending office actions are being processed across 3 distinct art units, showing a high degree of examiner and unit diversity for the active portfolio.
SHI, GENBIN is identified as the busiest examiner, holding 1 pending office action. With 3 distinct examiners each handling 1 of the 3 pending office actions, the institute's prosecution risk is spread across multiple individuals. The presence of 3 distinct art units suggests that the Biotechnology & Pharmaceuticals research being patented is varied enough to trigger different classification assignments. This distribution requires the institute to monitor 3 distinct examiners to ensure consistent results across its 3 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHI, GENBIN | 1 | — | — |
| AGGARWAL, SAHIL CHANDER | 1 | 66.7% | +0.0% |
| JOHNSON, TIRONE DEREK | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18840042 | MODULATION OF HUMAN BREAST MILK COMPOSITION | SHI, GENBIN | — |
| 18743767 | Methods and Compositions for Treating Fibroids | AGGARWAL, SAHIL CHANDER | — |
| 18558138 | COTH3 BINDING AGENTS AND USES THEREOF | JOHNSON, TIRONE DEREK | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1623 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18840042 | MODULATION OF HUMAN BREAST MILK COMPOSITION | SHI, GENBIN | 1628 | §102§103§112 | Non-Final OA | — | Pending | Aug 20, 2024 |
| 18743767 | Methods and Compositions for Treating Fibroids | AGGARWAL, SAHIL CHANDER | 1623 | §102§103§112 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18558138 | COTH3 BINDING AGENTS AND USES THEREOF | JOHNSON, TIRONE DEREK | 1674 | §112 | Non-Final OA | — | Pending | Oct 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLundquist Institute For Biomedical Innovation AT Harbor-Ucla Medical Center has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Genbin Shi has the most, with 1 of Lundquist Institute For Biomedical Innovation AT Harbor-Ucla Medical Center's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
